These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1581812)

  • 21. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
    Kattan S; Collins JP; Mohr D
    Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathological change of corpora cavernosa after long-term intracavernous injection.
    Hwang TI; Yang CR; Ho WL; Chu HW
    Eur Urol; 1991; 20(4):301-6. PubMed ID: 1814746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of papaverine versus prostaglandin E1 on penile blood flow by color duplex sonography.
    Liu LC; Wu CC; Liu LH; Chiang CP; Huang CH; Chou YH; Tan LB
    Eur Urol; 1991; 19(1):49-53. PubMed ID: 2007418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intracavernous injection of lipo prostaglandin E1 for the diagnosis of impotence: a comparative study with prostaglandin E1-CD].
    Yajima M; Baba K; Minagawa N; Kohno S; Haraguchi C; Iwamoto T; Osada T
    Hinyokika Kiyo; 1993 Mar; 39(3):289-92. PubMed ID: 8506803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
    Waldhauser M; Schramek P
    J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.
    Abdallah HM
    Int Urol Nephrol; 1998; 30(5):617-20. PubMed ID: 9934808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracavernosal injection of prostaglandin E1 as an alternative for papaverine in penile angiography.
    Wilms G; Peene P; Steeno O; Baert AL
    Urol Radiol; 1992; 14(1):59-61. PubMed ID: 1615576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with triple-drug therapy in a pharmacological erection program.
    Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
    J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of PGE1 in the treatment of erectile deficiency].
    Arena F; Peracchia G; Di Stefano C; Cortellini P
    Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simplified pharmacologic erection program for patients with spinal cord injury.
    Zaslau S; Nicolis C; Galea G; Britanico J; Vapnek JM
    J Spinal Cord Med; 1999; 22(4):303-7. PubMed ID: 10751135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction].
    Porst H
    Urologe A; 1988 Jan; 27(1):22-6. PubMed ID: 3284144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?
    Bassiem MA; Ismail IY; Salem TA; El-Sakka AI
    Urology; 2021 Feb; 148():173-178. PubMed ID: 33017615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.